Postmarket Assessment for Drugs and Biologics Used in Dermatology and Cutaneous Adverse Drug Reactions.

Reyes, Melissa; Kortepeter, Cindy; Muñoz, Monica

Reyes, Melissa; Kortepeter, Cindy; Muñoz, Monica.

Afiliação

Reyes M; Division of Pharmacovigilance, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA; Department of Dermatology, Uniformed Services University of the Health Sciences. Electronic address: Melissa.Reyes@fda.hhs.gov.
Kortepeter C; Division of Pharmacovigilance, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
Muñoz M; Division of Pharmacovigilance, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.

Dermatol Clin ; 40(3): 265-277, 2022 Jul.

Article em En | MEDLINE | ID: mdl-35750410

Assuntos

Produtos Biológicos; Dermatologia; Síndrome de Stevens-Johnson; Antibacterianos/efeitos adversos; Produtos Biológicos/efeitos adversos; Humanos; Pele; Síndrome de Stevens-Johnson/diagnóstico; Síndrome de Stevens-Johnson/epidemiologia; Síndrome de Stevens-Johnson/etiologia

Palavras-chave

Adverse event reporting; Cutaneous adverse drug reactions; Postmarket surveillance; Severe cutaneous adverse reactions; StevensJohnson syndrome; Toxic epidermal necrolysis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Assunto principal: Produtos Biológicos / Síndrome de Stevens-Johnson / Dermatologia Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Dermatol Clin Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google